Details of the Drug

General Information of Drug (ID: DMQ5APT)

Drug Name

QBW251

Synonyms

Icenticaftor; 1334546-77-8; Qbw251; Icenticaftor [INN]; Icenticaftor [USAN]; AMB0BO0WFH; QBW-251; 3-Amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-2-pyridinecarboxamide; 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)pyridine-2-carboxamide; (S)-3-Amino-6-methoxy-N-(3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)picolinamide; 2-Pyridinecarboxamide, 3-amino-6-methoxy-N-((2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl)-5-(trifluoromethyl)-; 2-pyridinecarboxamide, 3-amino-6-methoxy-N-[(2S)-3,3,3-trifluoro-2-hydroxy-2-methylpropyl]-5-(trifluoromethyl)-; UNII-AMB0BO0WFH; Icenticaftor [USAN:INN]; SCHEMBL2372751; CHEMBL4650318; GTPL11547; US10117858, Example 5; BDBM297402; DTXSID601336884; WHO 11246; AKOS040759841; compound 33 [PMID: 34028270]; MS-25717; HY-109177; CS-0116371; 3-amino-6-methoxy-5-trifluoromethyl-pyridine-2-carboxylic acid ((S)-3,3,3-trifluoro-2-hydroxy-2-methyl-propyl)-amide

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecule

Structure

3D MOL

2D MOL

Chemical Identifiers

Formula: C12H13F6N3O3
Canonical SMILES: CC(CNC(=O)C1=C(C=C(C(=N1)OC)C(F)(F)F)N)(C(F)(F)F)O
InChI: InChI=1S/C12H13F6N3O3/c1-10(23,12(16,17)18)4-20-8(22)7-6(19)3-5(11(13,14)15)9(21-7)24-2/h3,23H,4,19H2,1-2H3,(H,20,22)/t10-/m0/s1
InChIKey: USHQRIKZLHNPQR-JTQLQIEISA-N

Cross-matching ID

PubChem CID: 58442344
TTD ID: DFV1I4

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
cAMP-dependent chloride channel (CFTR)	TTRLZHP	CFTR_HUMAN	Potentiator	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	ClinicalTrials.gov (NCT04268823) A Randomized, Subjects and Investigator Blinded, Placebo Controlled Parallel Group Study to Assess the Mode of Action of QBW251 in Patients With Chronic Obstructive Pulmonary Disease (COPD). U.S.National Institutes of Health.
2	Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251). J Cyst Fibros. 2021 Mar;20(2):250-256.